| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| P A Ferchmin, Dinely Pérez, William Castro Alvarez, Mario A Penzo, Héctor M Maldonado, Vesna A Eterovi. γ-Aminobutyric acid type A receptor inhibition triggers a nicotinic neuroprotective mechanism. Journal of neuroscience research. vol 91. issue 3. 2013-10-17. PMID:23280428. |
nicotinic acetylcholine receptor (nachr)-mediated neuroprotection has been implicated in the treatment of neurodegenerative disorders such as alzheimer's and parkinson's diseases and hypoxic ischemic events as well as other diseases hallmarked by excitotoxic and apoptotic neuronal death. |
2013-10-17 |
2023-08-12 |
Not clear |
| B J Morley, R F Mervi. Dendritic spine alterations in the hippocampus and parietal cortex of alpha7 nicotinic acetylcholine receptor knockout mice. Neuroscience. vol 233. 2013-09-23. PMID:23270857. |
the α7 nicotinic acetylcholine receptor (nachr) is involved in higher cognitive and memory functions, and is associated with the etiology of neurological diseases involving cognitive decline, including alzheimer's disease (ad). |
2013-09-23 |
2023-08-12 |
mouse |
| Xue-ling Zhang, Xiao-lan Qi, Jia-mou Ren, Chang-xue Wu, Zhi-zhong Gua. [Effects of α3 neuronal nicotinic acetylcholine receptor on cell apoptosis and p38 MAPK signal transduction pathway in SH-SY5Y cells]. Zhonghua bing li xue za zhi = Chinese journal of pathology. vol 42. issue 2. 2013-09-16. PMID:23710919. |
to investigate the effects of α3 neuronal nicotinic acetylcholine receptor (nachr) on apoptosis and p38 signal transduction pathway in sh-sy5y cells and to assess the roles of α3 nachr in the pathogenesis of alzheimer's disease (ad). |
2013-09-16 |
2023-08-12 |
Not clear |
| T L Wallace, D Bertran. Importance of the nicotinic acetylcholine receptor system in the prefrontal cortex. Biochemical pharmacology. vol 85. issue 12. 2013-08-09. PMID:23628449. |
nicotinic receptors (nachrs) are a primary site of action for acetylcholine (ach), and the resulting pro-cognitive effects observed by stimulating nachrs with nicotine has long been appreciated by tobacco users, prompting investigation of therapeutic development for diseases (e.g., schizophrenia, alzheimer or attention-deficit-hyperactivity disorder) by targeting the neuronal nachr system. |
2013-08-09 |
2023-08-12 |
Not clear |
| Shi-Gao Chen, Ruo-Xu Gu, Hao Dai, Dong-Qing We. Virtual screening for alpha7 nicotinic acetylcholine receptor for treatment of Alzheimer's disease. Journal of molecular graphics & modelling. vol 39. 2013-07-03. PMID:23261879. |
our docking simulations and qsar modeling were reasonably accurate and predictive of nachr ligand affinity, and we have provided novel and reasonable computational methods for the virtual screening of possible α7 nachr agonists that may be effectively used for the treatment of various neural disorders, particularly alzheimer's disease. |
2013-07-03 |
2023-08-12 |
Not clear |
| Kai Ouyang, Xiao-lan Qi, Zhi-zhong Gua. [Influence of inhibited α7 nicotinic acetylcholine receptor gene expression on the production of β-amyloid peptide in SH-SY5Y cells]. Zhonghua bing li xue za zhi = Chinese journal of pathology. vol 41. issue 12. 2013-06-06. PMID:23324234. |
to investigate the influence of inhibited α7 neuronal nicotinic acetylcholine receptor (nachr) by small interference rna (sirna) in sh-sy5y cells and to explore the connection of these changes with the β-amyloid precursor protein (app) metabolism and the pathogenesis of alzheimer's disease (ad). |
2013-06-06 |
2023-08-12 |
Not clear |
| Anatoly A Mazurov, Lan Miao, Balwinder S Bhatti, Jon-Paul Strachan, Srinivasa Akireddy, Srinivasa Murthy, David Kombo, Yun-de Xiao, Philip Hammond, Jenny Zhang, Terry A Hauser, Kristen G Jordan, Craig H Miller, Jason D Speake, Gregory J Gatto, Daniel Yohanne. Discovery of 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (TC-6683, AZD1446), a novel highly selective α4β2 nicotinic acetylcholine receptor agonist for the treatment of cognitive disorders. Journal of medicinal chemistry. vol 55. issue 21. 2013-02-26. PMID:22793665. |
a novel potent and highly selective α4β2 nachr agonist 3-(5-chloro-2-furoyl)-3,7-diazabicyclo[3.3.0]octane (56, tc-6683, azd1446) with favorable pharmaceutical properties and in vivo efficacy in animal models has been identified as a potential treatment for cognitive deficits associated with psychiatric or neurological conditions and is currently being progressed to phase 2 clinical trials as a treatment for alzheimer's disease. |
2013-02-26 |
2023-08-12 |
Not clear |
| Riccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, Ilaria Ceccarelli, Giuseppe Cocconcelli, Thomas A Comery, John Dunlop, Eva Genesio, Chiara Ghiron, Simon N Haydar, Flora Jow, Laura Maccari, Iolanda Micco, Arianna Nencini, Carmela Pratelli, Carla Scali, Elisa Turlizzi, Michela Valacch. N-[5-(5-fluoropyridin-3-yl)-1H-pyrazol-3-yl]-4-piperidin-1-ylbutyramide (SEN78702, WYE-308775): a medicinal chemistry effort toward an α7 nicotinic acetylcholine receptor agonist preclinical candidate. Journal of medicinal chemistry. vol 55. issue 22. 2013-02-05. PMID:23083093. |
α7 nicotinic acetylcholine receptors (α7 nachr) represent promising therapeutic candidates for the treatment of cognitive impairment associated with alzheimer's disease (ad) and schizophrenia. |
2013-02-05 |
2023-08-12 |
Not clear |
| Ramakrishna Nirogi, Vishwottam Kandikere, Gopinadh Bhyrapuneni, Ramanatha Saralaya, Nageswararao Muddana, Prashanth Komarnen. Methyllycaconitine: a non-radiolabeled ligand for mapping α7 neuronal nicotinic acetylcholine receptors - in vivo target localization and biodistribution in rat brain. Journal of pharmacological and toxicological methods. vol 66. issue 1. 2012-11-29. PMID:22609758. |
reduction of cerebral cortical and hippocampal α7 neuronal nicotinic acetylcholine receptor (nachr) density was observed in the alzheimer's disease (ad) and other neurodegenerative diseases. |
2012-11-29 |
2023-08-12 |
rat |
| Karim A Alkadhi, Karem H Alzoubi, Marisa Srivareerat, Trinh T Tra. Elevation of BACE in an Aβ rat model of Alzheimer's disease: exacerbation by chronic stress and prevention by nicotine. The international journal of neuropsychopharmacology. vol 15. issue 2. 2012-09-27. PMID:21356140. |
in alzheimer's disease (ad), progressive accumulation of β-amyloid (aβ) peptides impairs nicotinic acetylcholine receptor (nachr) function by a mechanism that may involve α7 and α4β2-nachr subtypes. |
2012-09-27 |
2023-08-12 |
rat |
| Eleonora Palma, Luca Conti, Cristina Roseti, Cristina Limatol. Novel approaches to study the involvement of α7-nAChR in human diseases. Current drug targets. vol 13. issue 5. 2012-09-17. PMID:22300023. |
the alpha7 nicotinic acetylcholine receptor (α7 nachr) is widely distributed in the human brain and has been implicated in a number of human central nervous system (cns) diseases, including alzheimer's and parkinson's disease, schizophrenia and autism. |
2012-09-17 |
2023-08-12 |
human |
| Caterina M Hernandez, Kelly T Dinele. α7 nicotinic acetylcholine receptors in Alzheimer's disease: neuroprotective, neurotrophic or both? Current drug targets. vol 13. issue 5. 2012-09-17. PMID:22300028. |
several studies suggest that α7 nicotinic receptor (nachr) activation represents a useful therapeutic strategy for the cognitive impairments associated with early alzheimer's disease as the α7 subtype of nicotinic acetylcholine receptors are expressed by basal forebrain cholinergic projection neurons as well as by their targets in the hippocampus. |
2012-09-17 |
2023-08-12 |
mouse |
| Monica Neri, Stefano Bonassi, Patrizia Russ. Genetic variations in CHRNA7 or CHRFAM7 and susceptibility to dementia. Current drug targets. vol 13. issue 5. 2012-09-17. PMID:22300029. |
the presence of memory impairment and cognitive deficits in the alzheimer's disease (ad), dementia with lewy bodies (dlb), and pick's disease (pid) has been associated to dysfunction of cholinergic transmission, possibly due to the loss of cholinergic neurons and to the elimination of nachr in dementia patients. |
2012-09-17 |
2023-08-12 |
Not clear |
| Morten S Thomsen, Jens D Mikkelse. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets? Current drug targets. vol 13. issue 5. 2012-09-17. PMID:22300038. |
the α7 nicotinic acetylcholine receptor (nachr) is a promising drug target for a number of diseases ranging from schizophrenia and alzheimer's disease to chronic pain and inflammatory diseases. |
2012-09-17 |
2023-08-12 |
Not clear |
| Morten S Thomsen, Jens D Mikkelse. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets? Current drug targets. vol 13. issue 5. 2012-09-17. PMID:22300038. |
these regulatory proteins are often not expressed in in vitro models used to study α7 nachr function, and it is not known to what extent they are involved in diseases such as schizophrenia and alzheimer's disease. |
2012-09-17 |
2023-08-12 |
Not clear |
| Morten S Thomsen, Jens D Mikkelse. The α7 nicotinic acetylcholine receptor complex: one, two or multiple drug targets? Current drug targets. vol 13. issue 5. 2012-09-17. PMID:22300038. |
finally, we describe the special case of aβ1-42 binding to the α7 nachr, which may pose a unique challenge to drug development of α7 nachr-specific ligands for alzheimer's disease. |
2012-09-17 |
2023-08-12 |
Not clear |
| Riccardo Zanaletti, Laura Bettinetti, Cristiana Castaldo, Giuseppe Cocconcelli, Thomas Comery, John Dunlop, Giovanni Gaviraghi, Chiara Ghiron, Simon N Haydar, Flora Jow, Laura Maccari, Iolanda Micco, Arianna Nencini, Carla Scali, Elisa Turlizzi, Michela Valacch. Discovery of a novel alpha-7 nicotinic acetylcholine receptor agonist series and characterization of the potent, selective, and orally efficacious agonist 5-(4-acetyl[1,4]diazepan-1-yl)pentanoic acid [5-(4-methoxyphenyl)-1H-pyrazol-3-yl] amide (SEN15924, WAY-361789). Journal of medicinal chemistry. vol 55. issue 10. 2012-09-07. PMID:22468936. |
for this reason, α7 nachr agonists represent promising therapeutic candidates for the treatment of cognitive impairment associated with alzheimer's disease (ad) and schizophrenia. |
2012-09-07 |
2023-08-12 |
Not clear |
| Min Ding, Smita Ghanekar, Charles S Elmore, John R Zysk, Jennifer L Werkheiser, Chi-Ming Lee, Jianwei Liu, Vijay Chhajlani, Donna L Maie. [³H]Chiba-1001(methyl-SSR180711) has low in vitro binding affinity and poor in vivo selectivity to nicotinic alpha-7 receptor in rodent brain. Synapse (New York, N.Y.). vol 66. issue 4. 2012-05-21. PMID:22108786. |
neuronal nicotinic acetylcholine receptor (nachr) agonists active at the alpha-7 (α-7) receptor subtype are potential therapeutics for cognitive deficits in schizophrenia, alzheimer's disease, and other mental disorders. |
2012-05-21 |
2023-08-12 |
mouse |
| Morten S Thomsen, Mona El-Sayed, Jens D Mikkelse. Differential immediate and sustained memory enhancing effects of alpha7 nicotinic receptor agonists and allosteric modulators in rats. PloS one. vol 6. issue 11. 2012-04-10. PMID:22096516. |
the α7 nicotinic acetylcholine receptor (nachr) is a potential target for the treatment of cognitive deficits in patients with schizophrenia, adhd and alzheimer's disease. |
2012-04-10 |
2023-08-12 |
rat |
| Marie-Louise G Wadenberg, Ann-Kristin Fjällström, Malin Federley, Pernilla Persson, Pia Stenqvis. Effects of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effect liability: involvement of the cholinergic muscarinic receptor. The international journal of neuropsychopharmacology. vol 14. issue 5. 2012-01-06. PMID:20701827. |
the acetylcholine esterase inhibitor/cholinergic nicotinic receptor (nachr) allosteric modulator galantamine (gal) is used against cognitive impairment in alzheimer's disease. |
2012-01-06 |
2023-08-12 |
rat |